舒更葡糖钠
Tier B — Position earlySugammadex Sodium · all drugs expiring in 2028 →
Targets：Not applicable
Brand：Sugammadex Mylan、Bridion、布瑞亭
Indications (approved)：神经肌肉阻滞
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| SUGA-001 | - | - |
| SUGA-002 | - | - |
Frequently asked questions
What are the approved indications of Sugammadex Sodium?
Approved indications include: 神经肌肉阻滞.
When does the Sugammadex Sodium patent expire?
Based on public sources, the Sugammadex Sodium patent expires in 2028.
How many synthesis routes are recorded for Sugammadex Sodium?
1 synthesis routes are recorded; the shortest is 2 steps with 1.3 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Sugammadex Sodium intermediates?
All intermediates in Sugammadex Sodium routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Sugammadex Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24